MedTrace Logo

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

NCT05974410 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-10-02

No results posted yet for this study

Summary

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

Conditions

Interventions

DRUG

AVM0703

small molecule immunomodulatory drug

DRUG

Hydrocortisone

physiologic circadian glucocorticoid

DRUG

Proton pump inhibitor

Sponsors & Collaborators

  • AVM Biotechnology Inc

    lead INDUSTRY

Principal Investigators

  • Edward Loniewski, D.O. · AVM Biotechnology Inc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05974410 on ClinicalTrials.gov